Neuberger Berman Group
PLX icon

Neuberger Berman Group’s Protalix BioTherapeutics PLX Stock Holding History

Neuberger Berman Group’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.2K Buy
+11,629
New +$28.9K ﹤0.01% 2139
2018
Q3 		– Sell
-1,495
Closed -$6K – 1684
2018
Q2 		$6K Buy
+1,495
New +$6.64K ﹤0.01% 1699

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Neuberger Berman Group's PLX Position: Q1 2026 in Review

Neuberger Berman Group opened a new position in Protalix BioTherapeutics (PLX) in Q1 2026: 11,629 shares worth $25.2K. The stake represents ﹤0.01% of the portfolio and ranks #2139 among its holdings. This is a return to the name: Neuberger Berman Group previously reported a position in PLX as recently as Q2 2018.

Neuberger Berman Group first reported a position in PLX in Q2 2018 and has held it in 2 quarters since. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Neuberger Berman Group held 11,629 shares of Protalix BioTherapeutics worth $25.2K as of Q1 2026.
  • Protalix BioTherapeutics was a new Neuberger Berman Group position in Q1 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #2139 holding.
  • Neuberger Berman Group first reported a position in Protalix BioTherapeutics in Q2 2018 and has held it in 2 quarters since.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.